ALX Oncology Reveals Durable CD47 Blocker Responses in HER2-Positive Gastric Cancer at ASCO-GI At the 2025 ASCO Gastrointestinal Cancers Symposium, ALX Oncology presents promising Phase II data showing that evorpacept, a … 12 months ago By John In Pharma Industry Updates,Startups,Top Stories,